← Leaderboards
Sarat Chandarlapaty
Sloan-Kettering Inst Can Research
$10,852,142
Attributed
$13,463,375
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,463,375 · 10
By mechanism
R01$9,514,346 · 6
P50$2,167,269 · 2
R35$1,056,000 · 1
K08$725,760 · 1
Top collaborators
- David B. Solit5 shared
- Bob T Li3 shared
- Reuben S Harris1 shared
- Jorge Reis-Filho1 shared
- Rona Yaeger1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Luc Gordon Trang Morris$1,605,886
- Yelena Y Janjigian$1,716,445
- William Robert Jarnagin$4,049,789
- Timothy An-Thy Chan$21,076,830
- Jason S Lewis$26,024,327
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorSamplingGenomicsMalignant Breast NeoplasmResistanceMutationMalignant NeoplasmsMediatingErbb2 GenePathway InteractionsResponseInsightCell Free DnaMolecularCell LineEstrogen ReceptorsPhenotypeDependenceMutantMetastatic Breast CancerEsr1 GeneGenetic TranscriptionDrug ResistanceHormone Therapy
Grant awards (33)
Overcoming Resistance to Targeted Therapy in Breast Cancer$1,056,000
R35 · FY2025 · CA · contact PI
Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.$482,236
R01 · FY2025 · CA
HER2-mediated delivery of cytotoxic agents in solid tumors$558,399
R01 · FY2024 · CA · contact PI
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer$445,626
P50 · FY2024 · CA · contact PI
Defining the impact of mutant oncogene zygosity$384,644
R01 · FY2024 · CA · contact PI
Developmental Research Program$76,271
P50 · FY2024 · CA · contact PI
HER2-mediated delivery of cytotoxic agents in solid tumors$576,031
R01 · FY2023 · CA
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer$436,454
P50 · FY2023 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$402,618
R01 · FY2023 · CA
Defining the impact of mutant oncogene zygosity$396,790
R01 · FY2023 · CA · contact PI
HER2-mediated delivery of cytotoxic agents in solid tumors$576,029
R01 · FY2022 · CA
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer$422,764
P50 · FY2022 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$402,618
R01 · FY2022 · CA
Defining the impact of mutant oncogene zygosity$396,790
R01 · FY2022 · CA · contact PI
HER2-mediated delivery of cytotoxic agents in solid tumors$587,787
R01 · FY2021 · CA
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer$436,454
P50 · FY2021 · CA · contact PI
Therapeutic approaches to ER mutant breast cancer$410,835
R01 · FY2021 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$410,835
R01 · FY2021 · CA
Defining the impact of mutant oncogene zygosity$404,888
R01 · FY2021 · CA · contact PI
Implications and Vulnerabilities of APOBEC Mutagenesis in Breast Cancer$721,982
R01 · FY2020 · CA · contact PI
Therapeutic approaches to ER mutant breast cancer$410,835
R01 · FY2020 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$410,835
R01 · FY2020 · CA
Defining the impact of mutant oncogene zygosity$404,888
R01 · FY2020 · CA · contact PI
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer$349,700
P50 · FY2020 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$410,835
R01 · FY2019 · CA
Therapeutic approaches to ER mutant breast cancer$380,315
R01 · FY2019 · CA · contact PI
Therapeutic approaches to ER mutant breast cancer$392,078
R01 · FY2018 · CA · contact PI
Therapeutic approaches to ER mutant breast cancer$392,078
R01 · FY2017 · CA · contact PI
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer$145,152
K08 · FY2013 · CA · contact PI
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer$145,152
K08 · FY2012 · CA · contact PI
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer$145,152
K08 · FY2011 · CA · contact PI
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer$145,152
K08 · FY2010 · CA · contact PI
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer$145,152
K08 · FY2009 · CA · contact PI